Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Discovery of Dihydropyrimido-Pyrimidine-Based Bone Marrow Tyrosine Kinase Gene in Chromosome X Protein Proteolysis-Targeting Chimeras for the Treatment of Prostate Cancer.

ACS medicinal chemistry letters·2026

Same author

Pharmacological inhibition of PGK1 suppresses EGFR-positive esophageal squamous cell carcinoma by dual targeting of glycolysis and autophagy-dependent EGFR degradation.

Cellular oncology (Dordrecht, Netherlands)·2026

Same author

Targeting ROR1 with humanized antibody drug conjugates and cytokine fusion proteins for cancer therapy.

iScience·2026

Same author

BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis.

Signal transduction and targeted therapy·2026

Same author

Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs.

Nature communications·2026

Same author

Discovery of Novel Purine Derivatives as Potent and Orally Bioavailable PGK1 Inhibitors for the Treatment of Inflammatory Bowel Disease.

Journal of medicinal chemistry·2025

Search research articles

Related Experiment Video

Updated: Mar 22, 2026

Identification of Kinase-substrate Pairs Using High Throughput Screening

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

Discovery of a Highly Selective STK16 Kinase Inhibitor.

Feiyang Liu^1,2, Jinhua Wang³, Xingxing Yang¹

¹High Magnetic Field Laboratory, Chinese Academy of Sciences , 350 Shushanhu Road, P.O. Box 1110, Hefei, Anhui 230031, People's Republic of China.

ACS Chemical Biology

|April 16, 2016

Summary

A novel inhibitor, STK16-IN-1, selectively targets the STK16 protein kinase. This compound reduces cancer cell proliferation and enhances chemotherapy effects, offering a new tool for biological research.

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

Published on: May 12, 2017

Related Experiment Videos

Last Updated: Mar 22, 2026

Identification of Kinase-substrate Pairs Using High Throughput Screening

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

Published on: May 12, 2017

Area of Science:

Biochemistry
Molecular Biology
Cell Biology

Background:

Serine/threonine protein kinase 16 (STK16) is conserved in eukaryotes and involved in cellular processes like secretion.
The precise mechanisms of STK16's function remain largely unknown.
Targeted inhibition is crucial for dissecting STK16's biological roles.

Purpose of the Study:

To identify and characterize a selective inhibitor of STK16.
To investigate the cellular effects of STK16 inhibition.
To evaluate the potential of STK16 inhibition in combination cancer therapy.

Main Methods:

Screening of a focused kinase inhibitor library to discover STK16 inhibitors.
Biochemical assays to determine inhibitor potency (IC50) and kinome selectivity.
Cell-based assays (MCF-7 cells) using the inhibitor and RNAi for STK16 knockdown.
Combination studies with standard chemotherapeutic agents.

Main Results:

Discovery of STK16-IN-1, a potent and highly selective ATP-competitive inhibitor of STK16 (IC50 = 0.295 μM, S score = 0.0).
STK16-IN-1 treatment in MCF-7 cells led to decreased cell number and binucleated cell accumulation, mirroring STK16 RNAi effects.
Co-treatment with STK16-IN-1 slightly potentiated the antiproliferative activity of cisplatin, doxorubicin, colchicine, and paclitaxel.

Conclusions:

STK16-IN-1 is a valuable chemical probe for studying STK16 function.
STK16 plays a role in cell proliferation and cytokinesis.
Inhibition of STK16 may offer a strategy to enhance the efficacy of certain chemotherapies.